Iridex Corp (IRIX): Transforming Eye Care

Mar 9, 2026

Romeo Dizon, a finance executive with 35+ years who returned to lead cost cuts and cash management. Patrick Mercer, a 25–30 year medical device veteran steering Iridex’s operational turnaround and laser strategy. They discuss retina and glaucoma laser platforms, recurring probe revenue, Micropulse TLT potential, reimbursement trends, salesforce efficiency, cost-cutting moves, and plans for margin and growth expansion.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Lean Restructure Delivered Early Profit Momentum

Cost restructuring produced measurable financial improvement: 8% year-over growth and Q4 profitability signs.
Actions included 25% OPEX reduction and salesforce cut from 13 to 6 glaucoma reps while growing revenue.

ADVICE

Cut Costs Through Outsourcing And HQ Relocation

Trim fixed costs, outsource non-core back-office functions, and relocate to lower-cost facilities to preserve runway.
Iridex moved G&A work out of California and plans HQ move to South San Jose to save ~$600k/year.

INSIGHT

Policy Shift Favored Micropulse Reimbursement

MAC policy limiting stacked MIGS created a tailwind for Iridex because micropulse isn't classified as MIGS and remains reimbursable.
This allowed micropulse to be performed before/after concurrent MIGS procedures without losing reimbursement.

Get the Snipd Podcast app to discover more snips from this episode

Get the app